Healthwarehouse.Com (HEWA) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Healthwarehouse.Com $0.11, price $0.07, upside +50.0%, quality 55 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Healthwarehouse.Com for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $0.0700 – $0.2700 · fair‑value band $0.0770 – $0.1330 · the $0.0700 price screens below the $0.1050 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Follow Healthwarehouse.Com in your weekly email
Every Wednesday you see whether Healthwarehouse.Com is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
HealthWarehouse.com, Inc. operates an online and mail order pharmacy.
Show more
HealthWarehouse.com, Inc. operates an online and mail order pharmacy. It offers pharmacy supplies; diabetic supplies that include test strips, glucose meters, insulin syringes, and pen needles; over-the-counter products, such as products for allergy and sinus, diet and nutrition, digestive health, hair care, pain and fever, and personal care; home medical products; and pet supplies, which include flea and tick products, drugs for pets, and interceptors. The company sells prescription medications and OTC products to individual consumers over the Internet. HealthWarehouse.com, Inc. was founded in 2007 and is headquartered in Florence, Kentucky.
Stock analysis
Healthwarehouse.Com (HEWA) currently trades at $0.0700, while our model-based Fair Value estimate is $0.1050, implying the stock looks roughly 33.3% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $0.2900 per share, and 19 of the 21 models we run sit above the $0.0700 price.
Bear case: the Economic Profit group reads lowest at $0.0700, and 2 of the 21 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.0770 (bear) to $0.1330 (bull), the price of $0.0700 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Healthwarehouse.Com reported revenue of $49.0M in FY2025 versus $16.1M in FY2021, a compound +32.0%/yr. Reported net income was $265K in FY2025.
Key figures
Market cap $8.5M · P/S ratio 0.21 · EPS (TTM) $−0.0100 · Net margin 0.5% · Return on assets (EBIT) −15.0% · Operating margin −4.9% · Revenue (TTM) $40.3M · Revenue growth (YoY) −57.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 29 out of 100 (low confidence).
What moves the price
The share trades about 61% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 50%, HEWA screens cheaper than that median.
Fair Value models
Bear $0.0770Fair Value $0.1050Bull $0.1330
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.77/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+45.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.3%
Start year 2020 (pandemic). Over 10 years: +21.4% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.4%
’13
’14
’15
’16
’17
’18
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−17.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−17.8%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.0% → 1%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−15.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −17.1% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 61 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score55 · Above median
Fair Value upside+50% · Top 25%
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets0% · Below median
Net margin (TTM)−1% · Below median
Operating margin (TTM)−5% · Bottom 25%
Growth and dividend
Revenue growth−58% · Bottom 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM)0.21× · Cheaper than median
P/FCF8.0× · Priciest 25%
EV/EBITDA9.0× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)100· sector 33
FUTURE (revenue growth)0· sector 19
PAST (return on equity)0· sector 22
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 64
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Healthwarehouse.Com Fair Value". https://www.fairvalue-calculator.com/stock/HEWA
Frequently asked questions
Is Healthwarehouse.Com (HEWA) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.1050 versus a price of $0.0700, about +50% upside (undervalued).
What is the fair value of HEWA?
Our model-based fair value for Healthwarehouse.Com is $0.1050 (as of Sep 23, 2026), built from audited fundamentals. The current price: $0.0700.
What is the quality score of HEWA?
Healthwarehouse.Com has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Healthwarehouse.Com (HEWA)?
Our model-based price target is the fair value of $0.1050 (as of Sep 23, 2026) from 21 valuation models. Cautious scenario $0.0770, optimistic scenario $0.1330. It is a calculation from audited fundamentals, not an analyst target.
What is the Healthwarehouse.Com stock forecast for 2026?
Our models put fair value at $0.1050, about +50% upside versus a price of $0.0700 (undervalued). Cautious scenario $0.0770, optimistic scenario $0.1330. The calculation is refreshed regularly with new filings.
What is the revenue of Healthwarehouse.Com (HEWA)?
Healthwarehouse.Com reported trailing-twelve-month revenue of about $40.3M (latest available figure, as of Sep 23, 2026).
What growth is priced into Healthwarehouse.Com (HEWA)?
For today's price to be fair in a discounted-cash-flow model, Healthwarehouse.Com would have to grow free cash flow by -15.2 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +23.3 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of HEWA use?
Our models discount Healthwarehouse.Com at 8.5 %: a base by market capitalisation (nano), damped by beta 0.20, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Healthwarehouse.Com that is -15.2 % per year a year over ten years, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has Healthwarehouse.Com (HEWA) delivered so far?
Over the past 5 years revenue at Healthwarehouse.Com grew +23.3 % a year. The price currently implies -15.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Healthwarehouse.Com (HEWA) growing?
The median revenue growth in the sector is +2.6 % a year. That is the yardstick for the growth priced into Healthwarehouse.Com (-15.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Healthwarehouse.Com (HEWA)?
The free-cash-flow yield on the price is 26.76 %: that much free cash flow Healthwarehouse.Com produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Healthwarehouse.Com (HEWA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Healthwarehouse.Com it is $0.1050 per share (as of Sep 23, 2026), against a price of $0.0700. It is the blended result of 21 valuation models (cash flow, earnings, asset, dividend).
Is Healthwarehouse.Com stock overvalued or undervalued in 2026?
As of Sep 23, 2026, HEWA trades below its calculated fair value: price $0.0700, fair value $0.1050, a gap of about +50% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HEWA?
No. The price is what the market pays today ($0.0700); the fair value is what the company's own numbers justify ($0.1050). For Healthwarehouse.Com the two are $0.0350 per share apart. That gap is exactly why we show both numbers side by side.
How much is Healthwarehouse.Com worth?
The market values Healthwarehouse.Com at about $8.5M (market capitalisation, as of Sep 23, 2026). Per share that is $0.0700; our models calculate a fair value of $0.1050 per share.
What do the bullish and bearish scenarios say about HEWA?
Our models span a range for Healthwarehouse.Com: cautious scenario $0.0770, base $0.1050, optimistic $0.1330 per share (as of Sep 23, 2026, price $0.0700). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Healthwarehouse.Com (HEWA)?
Balance-sheet figures for Healthwarehouse.Com (as of Sep 23, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is HEWA from its 52-week high?
Healthwarehouse.Com trades at $0.0700, about 61% below its 52-week high of $0.1800 and at the low of $0.0700 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1050 is for.
Which stocks are comparable to Healthwarehouse.Com?
From the same area (Healthcare) we also value Alibaba Health Information Technology Limited, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Healthwarehouse.Com stock attractive at the current price?
The data as of Sep 23, 2026: price $0.0700, calculated fair value $0.1050 (+50%), Quality Score 55/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HEWA calculated?
We run Healthwarehouse.Com through 21 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.1050, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Healthwarehouse.Com currently trades 50 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Healthwarehouse.Com (HEWA)?
The closing price on Sep 23, 2026 was $0.0700. Our model-based fair value is $0.1050, about +50% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Healthwarehouse.Com right now?
The price is below even our cautious bear case ($0.0770). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (55/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Healthwarehouse.Com
How large is the market capitalisation of Healthwarehouse.Com (HEWA)?
The market capitalisation of Healthwarehouse.Com is $8.5M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Healthwarehouse.Com (HEWA)?
The price-to-sales ratio of Healthwarehouse.Com is 0.21 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Healthwarehouse.Com (HEWA)?
Earnings per share at Healthwarehouse.Com are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Healthwarehouse.Com (HEWA)?
The net margin of Healthwarehouse.Com is 0.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Healthwarehouse.Com (HEWA)?
On an EBIT basis the return on assets of Healthwarehouse.Com is −15.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Healthwarehouse.Com (HEWA)?
The operating margin of Healthwarehouse.Com is −4.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Healthwarehouse.Com (HEWA)?
Revenue at Healthwarehouse.Com is growing −57.8% versus a year earlier (3y avg +39.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Healthwarehouse.Com (HEWA) carry?
The net debt of Healthwarehouse.Com is $1.1M (fiscal year 2024, ≈ 1.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Healthwarehouse.Com in the live analysis
One click puts Healthwarehouse.Com on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026